Targeting BTK Signaling in B-Cell Malignancies

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

BTK as a Target in B-Cell Malignancies

Outcomes With Ibrutinib in Patients With R/R CLL by Chromosomal Abnormality and Karyotype

RESONATE: Ibrutinib vs Ofatumumab in Patients With Previously Treated CLL

RESONATE-2 Study Design

RESONATE-2 Patient Characteristics

RESONATE-2 Efficacy and Safety Outcomes

PFS by Prior Lines of Therapy RESONATE and RESONATE-2

Phase 2 Study of Ibrutinib in MCL

RESONATE Disposition and Treatment Exposure With Ibrutinib

OSU Experience Long-Term Ibrutinib in CLL

Predictors of Ibrutinib Discontinuation OSU Experience

Ibrutinib Resistance Mutations

Molecular Model of Ibrutinib Resistance

Real-World Discontinuation Rates with Ibrutinib

Toxicities Most Commonly Causing Ibrutinib Discontinuation in Real-World Setting

Real-World Efficacy Outcomes with Ibrutinib

Ibrutinib-Related Bleeding Across Trials

Anticoagulation and Ibrutinib-Related Bleeding

AF Incidence Over Time on Ibrutinib

Risk Factors for AF in Ibrutinib RCTs

Ibrutinib and VAs?

Maintain Awareness for VA

Practical Issues When Initiating Ibrutinib Drug-Drug Interactions

Screening Patients With Cardiac Risk

Ibrutinib Has Many Off-Target Effects

Acalabrutinib (ACP-196)

ACE-CL-001 Acalabrutinib Monotherapy in R/R CLL

ACE-CL-001 Outcomes

ELEVATE CLL R/R: Acalabrutinib vs Ibrutinib in Previously Treated High-Risk CLL

Acalabrutinib in MCL

Next-Generation BTK Inhibitors Zanubrutinib (BGB-3111)

Next-Generation BTK Inhibitors GS-4059 (ONO-4059)

Vecabrutinib (SNS-062) Activity Does Not Require C481

Key Takeaways

Abbreviations

Abbreviations (cont)

Abbreviations (cont)